Shopify turned in quarterly revenue and gross merchandise volume above estimates, but it wasn’t enough to lift shares. Shopify stock fell 8.4% to $109.85 in premarket trading Tuesday. For its fourth ...

It's been a strong day for Axsome Therapeutics. Its shares are now trading at $127.02, marking a 20.1% change since the ...

Real-time index price for TSX Energy Capped Index (TTEN), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Real-time index price for Nasdaq Composite [TR] (XCMP), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

NASDAQ AXSM opened at $106.46 on Wednesday. Axsome Therapeutics has a one year low of $64.11 and a one year high of $111.51. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.37 ...

This news article is based on a press release statement from Axsome Therapeutics (NASDAQ:AXSM). The company continues to focus on addressing critical gaps in CNS treatment and advancing patient ...

Axsome Therapeutics, Inc. AXSM announced that the FDA has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults. Per the company ...

Axsome Therapeutics has finally jumped all the hurdles in a challenging regulatory saga, winning approval for its oral migraine drug Symbravo. The rapid-acting treatment is approved for the acute ...

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ ... or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.

The FDA has approved Axsome Therapeutics’ Symbravo (meloxicam and rizatriptan), a novel acute treatment for adults with migraine with or without aura. According to the company, Symbravo employs Axsome ...

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...